Incretin Effect and Use After Clinical Islet Transplantation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by University of Alberta.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
University of Alberta
ClinicalTrials.gov Identifier:
NCT00768651
First received: October 7, 2008
Last updated: October 20, 2011
Last verified: October 2011
  Purpose

We aim to study if the administration of medications to increase the secretion of hormones from the intestines can improve glycemic control, reduce insulin use and promote β-cell regeneration/expansion in subjects with type 1 diabetes following islet transplantation who are back using small doses of insulin because of early graft dysfunction. We believe that the results will enable us to understand whether these drugs could be useful in islet transplant recipients, particularly if glycemic control deteriorates.


Condition Intervention Phase
Type 1 Diabetes
Drug: Pantoprazole
Drug: Sitagliptin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study of Safety and Efficacy of Combined Use of Dipeptidyl-peptidase Inhibitor (Sitagliptin) and Proton Pump Inhibitor (Pantoprazole) to Prevent Beta-cell Apoptosis and Promote Islet Regeneration in Islet Transplant Recipients With Early Graft Dysfunction

Resource links provided by NLM:


Further study details as provided by University of Alberta:

Primary Outcome Measures:
  • The primary endpoint will be insulin independence after 6 months of therapy. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Insulin independence after the 3 month washout period; insulin and C-peptide responses to the intravenous arginine and mixed meal tests; reduction in insulin use; and improvement in glycemic control as determined by HbA1c and CGMS. [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: October 2008
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Pantoprazole
    Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
    Other Name: Pantoloc
    Drug: Sitagliptin
    Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
    Other Name: Januvia
Detailed Description:

This is a single centre non-randomized pilot study. Subjects will be recruited from the current cohort of islet transplant recipients at the University of Alberta.

The primary objective off the study is to evaluate whether the combination of sitagliptin and pantoprazole can restore insulin independence in previously insulin independent islet transplant recipients experiencing early graft dysfunction. The study will also evaluate the safety of the combination drug therapy.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Subjects must meet the following criteria to be enrolled in this study:

  1. Male or female, aged 18 to 70, inclusive, who is a previous islet transplant recipient (at least 3 months since last islet transplant) and who received their transplant at the University of Alberta.
  2. Insulin independent for 3 months or longer after islet transplant.
  3. Early graft dysfunction as defined by:

    1. HbA1c >6% (but less than 7.5%); or
    2. fasting glucose > 7 mmol/L (126 mg/dl); or
    3. random glucose > 10 mmol/L (180 mg/dl), and
    4. Total insulin use of < 10 units/day.
  4. C-peptide positive.
  5. Able to provide informed consent.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

  1. Unable to provide informed consent.
  2. Prior therapy with sitagliptin or a proton pump inhibitor in the preceding 2 months.
  3. Vulnerable populations (i.e. cognitively impaired, pregnant women, residing in institutions, University of Alberta students or employees under the supervision of any of the investigators).
  4. Children, adolescent or patients with a "contraindication" or "warning" listed in the package insert of any of the study drugs:

    1. Hypersensitivity to sitagliptin or pantoprazole for any component of the formulation.
    2. Renal disease or renal dysfunction (as suggested by serum creatinine levels ≥ 136 µmol/L (males), ≥ 124 µmol/L (females) or abnormal creatinine clearance; or estimated by GFR <50 ml/min/1.73m2).
    3. Acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis).
  5. Uncontrolled hyperglycemia
  6. Any subject that in the opinion of the investigator would not be a good candidate for study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00768651

Locations
Canada, Alberta
University of Alberta - Clinical Islet Transplant Program
Edmonton, Alberta, Canada, T6G2C8
Sponsors and Collaborators
University of Alberta
Investigators
Principal Investigator: Peter Senior, MD, PhD University of Alberta
  More Information

No publications provided

Responsible Party: University of Alberta
ClinicalTrials.gov Identifier: NCT00768651     History of Changes
Other Study ID Numbers: 7331
Study First Received: October 7, 2008
Last Updated: October 20, 2011
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Pantoprazole
Proton Pump Inhibitors
Sitagliptin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 23, 2014